Evaluation Capacity-Building For A 'Migrant Children-Focused' Service

Special Studies Experience, Summer 2016 -- Xi'an City, China -- Partner Agencie(s): Shaanxi Xiaoci Social Development Centerhttp://deepblue.lib.umich.edu/bitstream/2027.42/134326/1/Poster_Cherylene_Aw_Peini_Ong.pd

Additive Manufacturable Materials for Electrochemical Biosensor Electrodes

With the impending Industrial Revolution 4.0, the information produced by sensors will be central in many applications. This includes the healthcare sector, where affordable healthcare and precision medicine are highly sought after. Electrochemical sensors have the potential to produce affordable, high sensitivity and specificity, intuitive, and rapid point‐of‐care diagnostics. Underpinning these achievements is the choice of material and the fabrication thereof. In this review, the different types of materials used in electrochemical biosensors are reported, with a focus on synthetic conductive materials. The review demonstrates that there is an abundance of materials to select from, and compositing different types of materials further widens their applicability in biosensors. In addition, the fabrication of such materials using the state‐of‐the‐art of fabrication technology, additive manufacturing (AM), is also detailed. The need for compositing is evident in AM, as the feedstock for certain AM technologies is inherently nonconductive. Both material choice and fabrication technologies limitations are also discussed to highlight opportunities for growth. The review highlights how recent technological advancements have the potential to drive the healthcare industry toward achieving its primary goals

Optical biosensors - Illuminating the path to personalized drug dosing

Optical biosensors are low-cost, sensitive and portable devices that are poised to revolutionize the medical industry. Healthcare monitoring has already been transformed by such devices, with notable recent applications including heart rate monitoring in smartwatches and COVID-19 lateral flow diagnostic test kits. The commercial success and impact of existing optical sensors has galvanized research in expanding its application in numerous disciplines. Drug detection and monitoring seeks to benefit from the fast-approaching wave of optical biosensors, with diverse applications ranging from illicit drug testing, clinical trials, monitoring in advanced drug delivery systems and personalized drug dosing. The latter has the potential to significantly improve patients' lives by minimizing toxicity and maximizing efficacy. To achieve this, the patient's serum drug levels must be frequently measured. Yet, the current method of obtaining such information, namely therapeutic drug monitoring (TDM), is not routinely practiced as it is invasive, expensive, time-consuming and skilled labor-intensive. Certainly, optical sensors possess the capabilities to challenge this convention. This review explores the current state of optical biosensors in personalized dosing with special emphasis on TDM, and provides an appraisal on recent strategies. The strengths and challenges of optical biosensors are critically evaluated, before concluding with perspectives on the future direction of these sensors

Disrupting 3D printing of medicines with machine learning.

3D printing (3DP) is a progressive technology capable of transforming pharmaceutical development. However, despite its promising advantages, its transition into clinical settings remains slow. To make the vital leap to mainstream clinical practice and improve patient care, 3DP must harness modern technologies. Machine learning (ML), an influential branch of artificial intelligence, may be a key partner for 3DP. Together, 3DP and ML can utilise intelligence based on human learning to accelerate drug product development, ensure stringent quality control (QC), and inspire innovative dosage-form design. With ML's capabilities, streamlined 3DP drug delivery could mark the next era of personalised medicine. This review details how ML can be applied to elevate the 3DP of pharmaceuticals and importantly, how it can expedite 3DP's integration into mainstream healthcare

Electrochemical biosensors: a nexus for precision medicine

Precision medicine is a field with huge potential for improving a patient's quality of life, wherein therapeutic drug monitoring (TDM) can provide actionable insights. More importantly, incorrect drug dose is a common contributor to medical errors. However, current TDM practice is time-consuming and expensive, and requires specialised technicians. One solution is to use electrochemical biosensors (ECBs), which are inexpensive, portable, and highly sensitive. In this review, we explore the potential for ECBs as a technology for on-demand drug monitoring, including microneedles, continuous monitoring, synthetic biorecognition elements, and multi-material electrodes. We also highlight emerging strategies to achieve continuous drug monitoring, and conclude by appraising recent developments and providing an outlook for the field

3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties

In the past decade, prescriptions for opioid medicines have been exponentially increasing, instigating opioid abuse as a global health crisis associated with high morbidity and mortality. In particular, diversion from the intended mode of opioid administration, such as injecting and snorting the opioid, is a major problem that contributes to this epidemic. In light of this, novel formulation strategies are needed to support efforts in reducing the prevalence and risks of opioid abuse. Here, modified release tramadol printlets (3D printed tablets) with alcohol-resistant and abuse-deterrent properties were prepared by direct powder extrusion three-dimensional printing. The printlets were fabricated using two grades of hydroxypropylcellulose (HPC). Both formulations displayed strong alcohol-resistance and had moderate abuse-deterrent properties. Polyethylene oxide (PEO) was subsequently added into the formulations, which improved the printlets' resistance to physical tampering in nasal inhalation tests and delayed their dissolution in solvent extraction tests. Overall, this article reports for the first time the use of direct powder extrusion three-dimensional printing to prepare drug products with both alcohol-resistant and abuse-deterrent properties. These results offer a novel approach for the safe and effective use of opioids that can be combined with the advantages that 3D printing provides in terms of on-demand dose personalisation

Harnessing Artificial Intelligence for the Next Generation of 3D Printed Medicines

Artificial intelligence (AI) is redefining how we exist in the world. In almost every sector of society, AI is performing tasks with super-human speed and intellect; from the prediction of stock market trends to driverless vehicles, diagnosis of disease, and robotic surgery. Despite this growing success, the pharmaceutical field is yet to truly harness AI. Development and manufacture of medicines remains largely in a ‘one size fits all’ paradigm, in which mass-produced, identical formulations are expected to meet individual patient needs. Recently, 3D printing (3DP) has illuminated a path for on-demand production of fully customisable medicines. Due to its flexibility, pharmaceutical 3DP presents innumerable options during formulation development that generally require expert navigation. Leveraging AI within pharmaceutical 3DP removes the need for human expertise, as optimal process parameters can be accurately predicted by machine learning. AI can also be incorporated into a pharmaceutical 3DP ‘Internet of Things’, moving the personalised production of medicines into an intelligent, streamlined, and autonomous pipeline. Supportive infrastructure, such as The Cloud and blockchain, will also play a vital role. Crucially, these technologies will expedite the use of pharmaceutical 3DP in clinical settings and drive the global movement towards personalised medicine and Industry 4.0

Effect of Erythropoietin on Haematological Parameters in Chronic Renal Failure Patients Undergoing Dialysis in Malaysia

Background: The worldwide rise in the number of patients with chronic renal failure (CRF). Chronic Renal Failure is a major health problem resulting in considerable increase in mortality and morbidity, decreased quality of life and heavy cost of therapies. . Objective: This study aims to evaluate the haematological parameters and iron status during monitoring of Chronic Renal Failure patients and to study the effects of subcutaneously and intravenously administered erythropoietin (EPO) in treating anaemia in Chronic Renal Failure patients. Methods: A retrospective record review study was conducted among the CRF patients treated at Hospital Pulau Pinang between 2005 and 2009. A total of 45 patients were randomly selected by using simple random sampling. The parameters were taken one to two weeks prior to EPO treatment and at 1 month and 3 months after EPO therapy was started. Data analyses were performed by using paired t test and independent t test via SPSS Version. 18.0.0. Results: After one month post-EPO, there was a significant difference of mean serum iron between continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis groups where the mean value of serum iron was higher in CAPD group. After three months post-EPO, there were significant differences of mean white blood cells and serum iron between the two groups. Conclusions: Chronic renal failure patients undergoing dialysis responded to EPO treatment and subcutaneous EPO administration appeared to give more favourable results compared to intravenous EPO.The authors of this study wish to thank the Ministry of Health, Malaysia, for thier giving us perminssion to conduct in this study and health staff of the Hospital Pulau Pinang, for their assistance during this study period. We would like to send our deepest thanks to all the partcipants who partcipated in this study

Inkjet drug printing onto contact lenses: Deposition optimisation and non-invasive dose verification

Inkjet printing has the potential to advance the treatment of eye diseases by printing drugs on demand onto contact lenses for localised delivery and personalised dosing, while near-infrared (NIR) spectroscopy can further be used as a quality control method for quantifying the drug but has yet to be demonstrated with contact lenses. In this study, a glaucoma therapy drug, timolol maleate, was successfully printed onto contact lenses using a modified commercial inkjet printer. The drug-loaded ink prepared for the printer was designed to match the properties of commercial ink, whilst having maximal drug loading and avoiding ocular inflammation. This setup demonstrated personalised drug dosing by printing multiple passes. Light transmittance was found to be unaffected by drug loading on the contact lens. A novel dissolution model was built, and in vitro dissolution studies showed drug release over at least 3 h, significantly longer than eye drops. NIR was used as an external validation method to accurately quantify the drug dose. Overall, the combination of inkjet printing and NIR represent a novel method for point-of-care personalisation and quantification of drug-loaded contact lenses